The linear progression through generations of BTK inhibitors may be a flawed strategy, as indefinite kinase blocking is unsustainable. The future likely lies in BTK degraders, a new drug class that eliminates the target protein entirely, offering a novel approach to overcoming resistance instead of just inhibiting the protein.

While second-generation BTK inhibitors are clinically similar, the next major advance in combination therapy may come from the BCL2 inhibitor component. The newer agent sonrotoclax is potentially more potent and selective than venetoclax, which could lead to superior efficacy and tolerability in future regimens.

Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.

When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.

A new agent, BGP-16673, works by destroying the BTK protein rather than just inhibiting it. This novel "degrader" mechanism is highly effective (75% response rate) in CLL patients who have developed resistance to covalent (e.g., ibrutinib), non-covalent (pirtobrutinib), and BCL-2 inhibitors, offering a new path for refractory disease.

Current oral BTK/BCL-2 inhibitor combinations for CLL have hit an MRD clearance "wall" of 35-50%. By upgrading the BCL-2 inhibitor to the more potent somatoclax, combined with zanubrutinib, MRD clearance rates nearly double to 98%, demonstrating that improving the BCL-2 component is key to achieving deeper remissions.

Despite advancements from first-generation (ibrutinib) to second-generation (acalabrutinib) BTK inhibitors, a consistent pattern emerges: the rate of complete responses plateaus around 36% over time. This suggests a potential biological limit for this class of drugs when used as monotherapy in CLL.

Improved T-cell function in CLL patients on BTK inhibitors is probably a result of the substantial reduction in disease burden, allowing the immune system to normalize. This effect is seen across different BTK inhibitors, challenging the older hypothesis that it was a specific off-target effect (ITK inhibition) of ibrutinib.

Pirtobrutinib's reduced side effects, like atrial fibrillation, stem from its precise targeting of BTK with minimal 'binding promiscuity' to other kinases. This makes it a safer option for patients who have already been on a less-targeted BTK inhibitor.